No Data
No Data
Ligand Pharmaceuticals Closed A Royalty Financing Agreement With Castle Creek Biosciences, Inc. To Support The Phase 3 Study Of D-Fi (FCX-007), Castle Creek's Lead Candidate, In Patients With Dystrophic Epidermolysis Bullosa
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Forecasting The Future: 5 Analyst Projections For XOMA Royalty
H.C. Wainwright Maintains XOMA Corp(XOMA.US) With Buy Rating, Cuts Target Price to $104
XOMA Corp(XOMA.US) 10% Shareholder Sells US$16.98 Million in Common Stock
XOMA Corp - 8.375% DP PFD B Declares $0.5234 Dividend